Literature DB >> 8786244

5-HT3 receptors: pharmacologic and therapeutic aspects.

L Gyermek1.   

Abstract

The serotonin 5-HT3 receptor is unique among the seven serotonin receptor "families" that have been recognized so far. It functions not as a G-protein coupled but as a direct ion channel gated receptor. Because of the varied neural functions linked to this receptor, intensive research interest has developed in recent years about its basic and clinical pharmacology, which are summarized in this review. Some new agonists and many new antagonists have been developed. These agents have a useful role as selective pharmacologic research probes, and some of them can be used therapeutically as potent and selective anti-nausea and antiemetic drugs, particularly in patients undergoing cancer chemotherapy treatment or general anesthesia procedures. Potential applications of these agents include the treatment of some behavioral disorders in mental disease, drug addiction, and certain types of pain syndromes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8786244     DOI: 10.1002/j.1552-4604.1995.tb04129.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  10 in total

Review 1.  General anaesthetic actions on ligand-gated ion channels.

Authors:  M D Krasowski; N L Harrison
Journal:  Cell Mol Life Sci       Date:  1999-08-15       Impact factor: 9.261

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

3.  Serotonin differentially modulates responses to tones and frequency-modulated sweeps in the inferior colliculus.

Authors:  L M Hurley; G D Pollak
Journal:  J Neurosci       Date:  1999-09-15       Impact factor: 6.167

Review 4.  5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.

Authors:  R E Gregory; D S Ettinger
Journal:  Drugs       Date:  1998-02       Impact factor: 9.546

Review 5.  Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.

Authors:  M I Wilde; A Markham
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

6.  Activation of serotonin 3 receptors changes in vivo auditory responses in the mouse inferior colliculus.

Authors:  Alexander Bohorquez; Laura M Hurley
Journal:  Hear Res       Date:  2009-02-21       Impact factor: 3.208

7.  From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics.

Authors:  Larry F Chu; De-Yong Liang; Xiangqi Li; Peyman Sahbaie; Nicole D'arcy; Guochun Liao; Gary Peltz; J David Clark
Journal:  Pharmacogenet Genomics       Date:  2009-03       Impact factor: 2.089

Review 8.  Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.

Authors:  J A Balfour; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 11.431

9.  Identification of Glycyrrhiza as the rikkunshito constituent with the highest antagonistic potential on heterologously expressed 5-HT3A receptors due to the action of flavonoids.

Authors:  Robin Herbrechter; Paul M Ziemba; Katrin M Hoffmann; Hanns Hatt; Markus Werner; Günter Gisselmann
Journal:  Front Pharmacol       Date:  2015-07-03       Impact factor: 5.810

10.  Kampo Medicine: Evaluation of the Pharmacological Activity of 121 Herbal Drugs on GABAA and 5-HT3A Receptors.

Authors:  Katrin M Hoffmann; Robin Herbrechter; Paul M Ziemba; Peter Lepke; Leopoldo Beltrán; Hanns Hatt; Markus Werner; Günter Gisselmann
Journal:  Front Pharmacol       Date:  2016-07-29       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.